In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

Data ReadoutVERVE-102Positive

AI Analysis

Summary

Verve Therapeutics' VERVE-102, an in vivo base editor targeting PCSK9, was published in the New England Journal of Medicine for treatment of hypercholesterolemia, representing significant clinical validation of the gene editing approach.

Importance:7/10

Sentiment:

0.70

base editingPCSK9hypercholesterolemiagene therapyNEJM publication

Related Companies

$VERV

Read the original article

Published by New England Journal of Medicine on May 25, 2026 12:45 PM

Read Original